2021-2030 Analysis and Review Lipid Lowering Drugs Market
Lipid Lowering Drugs Market By Drug Class (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, PCSK9 Inhibitors, Combination and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The lipid lowering drugs market was valued at USD 20,605.0 Mn by 2019. The rising prevalence of hyperlipidemia in the young adult population worldwide primarily drives the lipid lowering drugs market growth. Promising drug pipeline and effective implementation of treatment guidelines for lowering blood cholesterol levels further accentuate the market growth.
Hyperlipidemia is the most predominant risk factor associate with the high mortality rate I patients suffering from coronary artery disease. As per the latest statistics provided by the World Health Organization (WHO), it is anticipated that high blood cholesterol levels are responsible annually for 2.6 million deaths and 29.7 million disability-adjusted life years (DALYs), throughout the globe. The medications need to be taken under strict medical supervision to prevent the occurrence of unwanted drug-related adverse events.
The major segments related to the lipid lowering drugs market are:
By Drug Class (2017–2027; US$ Mn)
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Others
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment (2017–2027; US$ Mn)
North America
U.S.
Canada
Europe
United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
The study includes the profiles of major market players with a significant global and regional presence along with top company positioning.
Significant customers?
Segment Analysis
Statins are representing the largest market share in the drug class segment for lipid lowering drugs market. It is the most frequently prescribed medication for lowering the high blood cholesterol levels via the inhibition of HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase which is a rate-limiting enzyme in the cholesterol biosynthesis pathway. In the last 2 decades, it has been vital in lowering the mortality rate associated with coronary artery disease worldwide. PCSK9 inhibitors are expected to highlight excellent market growth during the forecast period owing to its pronounced therapeutic efficacy in statin-intolerant and statin resistant patients. It is vital in lowering the number of LDLR expression in the hepatocytes and enhances its metabolism by promoting its subsequent degradation.
Hospital pharmacy is reigning the distribution channel segment for lipid lowering drugs market. Precise dispensing of lipid lowering drugs by hospital pharmacists is mandatory as the majority of them are associated with serious side effects such as skin rashes, dizziness, sleep problems, etc. Retail pharmacy is expected to grow at a comfortable pace owing of the provision of government-subsidized lipid lowering drugs at lower affordable prices in the retail stores of the developing region.
North America is presently leading the geography segment for lipid lowering drugs market. The growing incidence of high blood cholesterol levels among the young population primarily drives the market growth in the region. The presence of well-established healthcare infrastructure and affordable reimbursement scenarios together accentuate the market growth in the region. Furthermore, the domicile of major players such as Pfizer, Inc., Amgen, Inc., Merck Co., Inc., AbbVie, Inc., etc further propels the market growth in the region. Europe is the second-largest regional segment due to the effective implementation of the treatment guidelines postulated by the European Medical Agency (EMA), for the treatment of hyperlipidemia prevalent in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the lipid lowering drugs market. An unhealthy lifestyle, craving for junk food, stress, etc. are responsible for the market growth in the region.
$4,600 | |
$6,600 | |
$13,200 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |